A5019577735- Multiple Myeloma Research and Treatments
- Hematopoietic Stem Cell Transplantation
- Cancer Treatment and Pharmacology
- Acute Myeloid Leukemia Research
- Medical Imaging and Pathology Studies
- Chronic Lymphocytic Leukemia Research
- Neutropenia and Cancer Infections
- Lung Cancer Diagnosis and Treatment
- Histone Deacetylase Inhibitors Research
- Polyomavirus and related diseases
- Acute Lymphoblastic Leukemia research
- Renal Transplantation Outcomes and Treatments
- Actinomycetales infections and treatment
- Chronic Myeloid Leukemia Treatments
Dana-Farber Cancer Institute
2020-2024
Jersey City Medical Center
2019
The ability of posttransplant cyclophosphamide (PTCY) to facilitate haploidentical transplantation has spurred interest in whether PTCY can improve clinical outcomes patients with HLA-matched unrelated donors undergoing peripheral blood stem cell (PBSCT). We investigated our institutional experience using PTCY-based graft-versus-host disease (GVHD) prophylaxis compared conventional tacrolimus-based regimens. overall survival, progression-free survival (PFS), relapse, nonrelapse mortality,...
Chronic graft-versus-host disease (cGVHD) is a leading cause of late morbidity and mortality after allogenic hematopoietic stem cell transplantation. Corticosteroid-based therapies are mainstay its initial treatment but there no consensus in how to treat steroid-refractory cGVHD. Ibrutinib Bruton tyrosine kinase IL-2-inducible inhibitor thought affect pathways driving cGVHD, it was approved for the refractory cGVHD by Food Drug Administration (FDA) August 2017 landmark phase 1b/2 study. It...